Skip to Main Content

Author Details

Britta Weigelt
Memorial Sloan Kettering Cancer Center
2002
311
76
PMIDPaper TitleJournal TitlePublished Year
37925055Nonlobular Invasive Breast Carcinomas with Biallelic Pathogenic CDH1 Somatic Alterations: A Histologic, Immunophenotypic, and Genomic Characterization.Mod Pathol2024
38013631Decreased HER2 expression in endometrial cancer following anti-HER2 therapy.J Pathol2024
37886874Pathogenic germline variants in patients with endometrial cancer of diverse ancestry.Cancer2024
36007103High-Sensitivity Mutation Analysis of Cell-Free DNA for Disease Monitoring in Endometrial Cancer.Clin Cancer Res2023
37558129HER2 Genetic Intratumor Heterogeneity Is Associated With Resistance to Trastuzumab and Trastuzumab Emtansine Therapy in Recurrent High-Grade Endometrial Cancer.Mod Pathol2023
37587346Long-molecule scars of backup DNA repair in BRCA1- and BRCA2-deficient cancers.Nature2023
37584555Endometrial/Endometrioid Stromal Tumors With Extensive Whorling and CTNNB1 Translocation : A Report of 3 Cases.Am J Surg Pathol2023
37652400DNA Methylation Signature of Synchronous Endometrioid Endometrial and Ovarian Carcinomas.Mod Pathol2023
37945902Most large structural variants in cancer genomes can be detected without long reads.Nat Genet2023
37651310Molecular Characterization of Endometrial Carcinomas in Black and White Patients Reveals Disparate Drivers with Therapeutic Implications.Cancer Discov2023
37738546Germline Pathogenic Variants and Genetic Counseling by Ancestry in Patients With Epithelial Ovarian Cancer.JCO Precis Oncol2023
37609261Interferon response and epigenetic modulation by <i>SMARCA4</i> mutations drive ovarian tumor immunogenicity.bioRxiv2023
37643132Assessing the Genomic Landscape of Cervical Cancers: Clinical Opportunities and Therapeutic Targets.Clin Cancer Res2023
37636495Tumor lenvatinib addiction and withdrawal rebound response in patients with advanced endometrial cancer.Gynecol Oncol Rep2023
36958196Landscape of chromatin remodeling gene alterations in endometrial carcinoma.Gynecol Oncol2023
37149903Germline drivers of gynecologic carcinosarcomas.Gynecol Oncol2023
37245486Integration of clinical sequencing and immunohistochemistry for the molecular classification of endometrial carcinoma.Gynecol Oncol2023
37438207Response to Letter to the Editor, Gilks et al.Gynecol Oncol2023
37195235A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer.Clin Cancer Res2023
36617679Ovarian RASoma With Mesonephric-like Adenocarcinoma and Mixed Mullerian Components: A Case Report With Molecular Analysis Demonstrating Multidirectional Mullerian Differentiation.Int J Gynecol Pathol2023
36744932Comprehensive analysis of germline drivers in endometrial cancer.J Natl Cancer Inst2023
36804617Impact of immune infiltration signatures on prognosis in endometrial carcinoma is dependent on the underlying molecular subtype.Gynecol Oncol2023
36641897EBCC-13 manifesto: Balancing pros and cons for contralateral prophylactic mastectomy.Eur J Cancer2023
36828363NR4A3 Expression Is Consistently Absent in Acinic Cell Carcinomas of the Breast: A Potential Nosologic Shift.Mod Pathol2023
36302256Cervical Pleuropulmonary Blastoma-like Tumor Associated With DICER1 and TP53 Mutations.Int J Gynecol Pathol2023
36355783Molecular Characterization of Acquired Resistance to KRASG12C-EGFR Inhibition in Colorectal Cancer.Cancer Discov2023
36323507<i>KIT</i> genetic alterations in breast cancer.J Clin Pathol2023
33148628Neuroendocrine tumours of the breast: a genomic comparison with mucinous breast cancers and neuroendocrine tumours of other anatomic sites.J Clin Pathol2022
35411948Recurrent WWTR1 S89W mutations and Hippo pathway deregulation in clear cell carcinomas of the cervix.J Pathol2022
35443055MAPK Pathway Genetic Alterations Are Associated with Prolonged Overall Survival in Low-Grade Serous Ovarian Carcinoma.Clin Cancer Res2022
35676169Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated With Neoadjuvant Chemotherapy.Clin Genitourin Cancer2022
35545680Fundamental immune-oncogenicity trade-offs define driver mutation fitness.Nature2022
35545291Treatment of ovarian clear cell carcinoma with immune checkpoint blockade: a case series.Int J Gynecol Cancer2022
35439652Evaluation of TERT mRNA expression using RNAscope®: A potential histopathologic diagnostic and prognostic tool.Pathol Res Pract2022
35641605Author Correction: Fundamental immune-oncogenicity trade-offs define driver mutation fitness.Nature2022
35793549Impact of obesity and white adipose tissue inflammation on the omental microenvironment in endometrial cancer.Cancer2022
35699480Genomic Determinants of Early Recurrences in Low-Stage, Low-Grade Endometrioid Endometrial Carcinoma.J Natl Cancer Inst2022
35365770Genomic landscape of endometrial carcinomas of no specific molecular profile.Mod Pathol2022
35816189Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes.Clin Cancer Res2022
35484264Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA.Nat Med2022
35849120Microsatellite Instability-High Endometrial Cancers with MLH1 Promoter Hypermethylation Have Distinct Molecular and Clinical Profiles.Clin Cancer Res2022
36551247Comprehensive Genomic Profiling of Cell-Free Circulating Tumor DNA Detects Response to Ribociclib Plus Letrozole in a Patient with Metastatic Breast Cancer.Biomolecules2022
36517593Ovarian cancer mutational processes drive site-specific immune evasion.Nature2022
36177509Vulvar angiomyofibroblastoma is molecularly defined by recurrent MTG1-CYP2E1 fusions.Histopathology2022
36368707Management of patients with early-stage ovarian clear cell carcinoma: risk stratification and fertility conservation.Int J Gynecol Cancer2022
36138078Mullerian adenosarcoma: clinicopathologic and molecular characterization highlighting recurrent BAP1 loss and distinctive features of high-grade tumors.Mod Pathol2022
36240474Risk Stratification of Stage I Grade 3 Endometrioid Endometrial Carcinoma in the Era of Molecular Classification.JCO Precis Oncol2022
36265117Germline <i>SMARCA4</i> Deletion as a Driver of Uterine Cancer: An Atypical Presentation.JCO Precis Oncol2022
36289342Single-cell genomic variation induced by mutational processes in cancer.Nature2022
36253302Gastric-type adenocarcinoma of the cervix: Clinical outcomes and genomic drivers.Gynecol Oncol2022
  • 1 - 50 of 311

Recommended Authors

Amy Lum
University of British Columbia
Career Start Year 2014
Number of shared co-authors 26
Yuexin Liu
The University of Texas MD Anderson Cancer Center
Career Start Year 2011
Number of shared co-authors 10
Hans Kristian Moen Vollan
F Hoffmann-La Roche Ltd
Career Start Year 2010
Number of shared co-authors 9
Oscar Krijgsman
The Netherlands Cancer Institute
Career Start Year 2008
Number of shared co-authors 6
Leonard Da Silva
Pathology Queensland The Royal Brisbane and Women's Hospital Brisbane Qld Australia.
Career Start Year 2007
Number of shared co-authors 11
Samuel Leung
University of British Columbia
Career Start Year 2007
Number of shared co-authors 33
Christina Yau
University of California San Francisco
Career Start Year 2005
Number of shared co-authors 14
Markus Riester
Novartis Institutes for BioMedical Research
Career Start Year 2005
Number of shared co-authors 4
Albrecht Stenzinger
Institute of Pathology, University Hospital Heidelberg
Career Start Year 2005
Number of shared co-authors 13
Joshy George
Peter MacCallum Cancer Centre
Career Start Year 2005
Number of shared co-authors 28
Tuan Zea Tan
Cancer Science Institute of Singapore, National University of Singapore
Career Start Year 2005
Number of shared co-authors 22
Katherine A Hoadley
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Career Start Year 2004
Number of shared co-authors 31
Leah M Prentice
British Columbia Women's Hospital and Health Centre
Career Start Year 2004
Number of shared co-authors 17
Christina Curtis
Stanford University School of Medicine
Career Start Year 2004
Number of shared co-authors 18
Peter T Simpson
UQ Centre for Clinical Research, The University of Queensland
Career Start Year 2003
Number of shared co-authors 18
Peter Horak
German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
Career Start Year 2003
Number of shared co-authors 4
Sherri Z Millis
Foundation Medicine Inc
Career Start Year 2003
Number of shared co-authors 5
Joel S Parker
Lineberger Cancer Center, University of North Carolina
Career Start Year 2002
Number of shared co-authors 24
Siddhartha Deb
Olivia Newton-John Cancer Research Institute
Career Start Year 2002
Number of shared co-authors 3
Darran P O'Connor
UCD Conway Institute, University College Dublin
Career Start Year 2001
Number of shared co-authors 1
Steve E Kalloger
University of British Columbia
Career Start Year 2000
Number of shared co-authors 16
Richard B Schwab
Department of Medicine and Moores Cancer Center, University of California San Diego
Career Start Year 2000
Number of shared co-authors 4
Kenna R Mills Shaw
The University of Texas MD Anderson Cancer Center
Career Start Year 1999
Number of shared co-authors 12
Jun Yao
The University of Texas MD Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 7
Ingrid Hedenfalk
Lund University and Skane University Hospital
Career Start Year 1997
Number of shared co-authors 10
Jan Budczies
Institute of Pathology, University Hospital Heidelberg
Career Start Year 1996
Number of shared co-authors 5
Susan J Done
University Health Network
Career Start Year 1994
Number of shared co-authors 2
Janine Senz
University of British Columbia
Career Start Year 1994
Number of shared co-authors 34
Rosemary L Balleine
Westmead Institute for Medical Research, The University of Sydney
Career Start Year 1993
Number of shared co-authors 24
Carlos Caldas
Cancer Research UK Cambridge Institute, University of Cambridge
Career Start Year 1992
Number of shared co-authors 41

Collaborators

Jorge S Reis-Filho
Memorial Sloan-Kettering Cancer Center
Co-authored papers 210
Arnaud Da Cruz Paula
Memorial Sloan Kettering Cancer Center
Co-authored papers 72
Pier Selenica
Memorial Sloan Kettering Cancer Center
Co-authored papers 69
Charlotte K Y Ng
University of Bern
Co-authored papers 68
Salvatore Piscuoglio
University of Basel
Co-authored papers 55
Felipe C Geyer
Instituto Do Cancer Do Estado de Sao Paulo
Co-authored papers 50
Robert A Soslow
Co-authored papers 42
Hannah Y Wen
Memorial Sloan Kettering Cancer Center
Co-authored papers 40
Larry Norton
Memorial Sloan Kettering Cancer Center
Co-authored papers 40
Raymond S Lim
Memorial Sloan Kettering Cancer Center
Co-authored papers 28
David N Brown
Memorial Sloan Kettering Cancer Center
Co-authored papers 26
Luciano G Martelotto
Monash University
Co-authored papers 23
Michael F Berger
Co-authored papers 22
Kathleen A Burke
Brown University
Co-authored papers 22
Caterina Marchi??
University of Turin, Candiolo Cancer Institute, FPO-IRCCS
Co-authored papers 22
Lora H Ellenson
Memorial Sloan Kettering Cancer Center
Co-authored papers 20
Nadeem Riaz
Memorial Sloan Kettering Cancer Center
Co-authored papers 18
Alan Mackay
Co-authored papers 16
Maryou B Lambros
The Institute of Cancer Research
Co-authored papers 15
Brian P Rubin
Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic
Co-authored papers 15
Ronglai Shen
Co-authored papers 14
Rahul Kumar
Roswell Park Comprehensive Cancer Center
Co-authored papers 14
Laura J Van't Veer
University of California San Francisco
Co-authored papers 14
Marc Ladanyi
Memorial Sloan Kettering Cancer Center
Co-authored papers 13
Rita A Sakr
Universite Libre de Bruxelles
Co-authored papers 12
Nicola Fusco
IEO European Institute of Oncology IRCCS
Co-authored papers 12
Alan Ashworth
UCSF Helen Diller Family Comprehensive Cancer Center
Co-authored papers 11
Melissa P Murray
Memorial Sloan Kettering Cancer Center
Co-authored papers 11
Tari A King
Co-authored papers 9
Simon N Powell
Memorial Sloan Kettering Cancer Center
Co-authored papers 9
Release 1.2